Phase II trial of menogaril in advanced colorectal cancer. 1988

E E Holdener, and W W ten Bokkel Huinink, and G Decoster, and C Ludwig, and G Renard, and H M Pinedo
Division of Oncology and Hematology, Medizinische Klinik C, Kantonsspital, St Gallen, Switzerland.

Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg/sqm or 200 mg/sqm repeated every 4 weeks. Twenty-seven patients were evaluable for response and no objective responses were achieved. Myelosuppression, only leukopenia, was usually of mild-moderate degree and occurred in 63% of the patients. Twenty-seven percent of the patients experienced severe leukopenia. Local erythema and phlebitis were frequently observed and were severe in 13% of the patients. Nausea/vomiting (66%) and alopecia (50%) were. of mild-moderate degree. This study suggests that menogaril at these doses and schedule had no activity in advanced colorectal cancer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009621 Nogalamycin An anthrocycline from a Streptomyces nogalater variant. It is a cytolytic antineoplastic that inhibits DNA-dependent RNA synthesis by binding to DNA. U-15167,U 15167,U15167
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006403 Hematologic Tests Tests used in the analysis of the hemic system. Blood Tests,Hematologic Test,Hematological Tests,Test, Hematologic,Tests, Hematologic,Blood Test,Hematological Test,Test, Blood,Test, Hematological,Tests, Blood,Tests, Hematological
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E E Holdener, and W W ten Bokkel Huinink, and G Decoster, and C Ludwig, and G Renard, and H M Pinedo
September 1987, Cancer treatment reports,
E E Holdener, and W W ten Bokkel Huinink, and G Decoster, and C Ludwig, and G Renard, and H M Pinedo
November 1987, European journal of cancer & clinical oncology,
E E Holdener, and W W ten Bokkel Huinink, and G Decoster, and C Ludwig, and G Renard, and H M Pinedo
November 1982, Cancer treatment reports,
E E Holdener, and W W ten Bokkel Huinink, and G Decoster, and C Ludwig, and G Renard, and H M Pinedo
January 1990, European journal of cancer (Oxford, England : 1990),
E E Holdener, and W W ten Bokkel Huinink, and G Decoster, and C Ludwig, and G Renard, and H M Pinedo
August 1981, European journal of cancer & clinical oncology,
E E Holdener, and W W ten Bokkel Huinink, and G Decoster, and C Ludwig, and G Renard, and H M Pinedo
September 1988, Journal of the National Cancer Institute,
E E Holdener, and W W ten Bokkel Huinink, and G Decoster, and C Ludwig, and G Renard, and H M Pinedo
August 1991, Investigational new drugs,
E E Holdener, and W W ten Bokkel Huinink, and G Decoster, and C Ludwig, and G Renard, and H M Pinedo
August 1990, Investigational new drugs,
E E Holdener, and W W ten Bokkel Huinink, and G Decoster, and C Ludwig, and G Renard, and H M Pinedo
October 1987, Cancer treatment reports,
E E Holdener, and W W ten Bokkel Huinink, and G Decoster, and C Ludwig, and G Renard, and H M Pinedo
June 1987, Cancer treatment reports,
Copied contents to your clipboard!